Outcome of the Board Meeting held on May 21, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals reported audited standalone financial results for FY 2026. Total income stood at Rs. 310.70 Lakhs vs Rs. 307.33 Lakhs in previous year (0.7% growth). Revenue from operations grew 7.2% to Rs. 282.79 Lakhs from Rs. 263.74 Lakhs. PAT increased 28.5% to Rs. 10.15 Lakhs from Rs. 7.90 Lakhs. EPS improved to Rs. 0.17 from Rs. 0.16. The company raised Rs. 112.83 Lakhs through conversion of 10,75,000 warrants. Cash and cash equivalents declined sharply from Rs. 30.24 Lakhs to Rs. 5.82 Lakhs. Statutory auditors issued an unmodified opinion (clean audit).
The company shows steady PAT growth of 28.5% but weak revenue growth and a concerning drop in cash reserves. The sharp decline in cash position and negative operating cashflow despite profit growth warrants monitoring.